Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19255977 | 0.97 | CRBN (0.41) | CRBNKDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL346851 | 0.97 | CRBN (0.41) | CRBNKDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL9238801 | 0.97 | CRBN (0.41) | CRBNKDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL19585725 | 0.88 | CRBN (0.44) | CRBNKDM4ELMNACYP2C19TSHR | |
| SCHEMBL22271225 | 0.85 | CRBN (0.48) | CRBNKDM4ELMNACYP2C19 | |
| SCHEMBL20633686 | 0.81 | NEK2 (0.36) | CRBNKDM4ELMNACYP2C19TSHR | |
| SCHEMBL2527186 | 0.78 | NEK2 (0.41) | CRBNKDM4ELMNACYP2C19TSHR | |
| SCHEMBL2522078 | 0.76 | OPRM1 (0.47) | CRBNSMN1; SMN2 | |
| SCHEMBL428515 | 0.75 | — | — | |
| SCHEMBL6229229 | 0.74 | OPRM1 (0.46) | CRBNSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| CN-117630202-B | Method for detecting buspirone hydrochloride intermediate impurities | 山东泰合医药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-117630202-A | Method for detecting buspirone hydrochloride intermediate impurities | 山东泰合医药科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117229212-A | Preparation method of 3, 3-tetramethylene glutarimide | 太仓运通新材料科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230271142-A1 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | MICROPORE TECHNOLOGIES LIMITED (GB) | 2023-08-31 | — | — | US | claimed |
| EP-4188570-A2 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | Micropore Technologies Limited (GB) | 2023-06-07 | — | — | EP | claimed |
| EP-2768537-B1 | ACRYLIC POLYMER FORMULATIONS | PURDUE PHARMA LP (US) | 2019-02-20 | — | — | EP | claimed |
| US-9974839-B2 | Self-assembled toroidal-spiral particles and manufacture and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-05-22 | — | — | US | claimed |
| US-20160310433-A1 | Acrylic Polymer Formulations | PURDUE PHARMA LP (US) | 2016-10-27 | — | — | US | claimed |
| US-20150030686-A1 | SELF-ASSEMBLED TOROIDAL-SPIRAL PARTICLES AND MANUFACTURE AND USES THEREOF | UNIV ILLINOIS (US) | 2015-01-29 | — | — | US | claimed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | claimed |
| EP-0720850-A1 | Method for the diagnosis of a dysfunction of 5-HT 1A receptors | EARLOW LIMITED (IE) | 1996-07-10 | — | — | EP | claimed |
| US-5403848-A | Diagnosis and treatment of a disorder of the gastrointestinal tract | EARLOW LIMITED (IE) | 1995-04-04 | — | — | US | claimed |
| US-5324738-A | Diagnosis and treatment of a disorder of the gastrointestinal tract | EARLOW LIMITED (IE) | 1994-06-28 | — | — | US | claimed |
| US-5158956-A | Administering serotonin receptor agonist | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| EP-0419237-A2 | Treatment of non ulcerative dyspepsia with cyproheptadine | EARLOW LIMITED (IE) | 1991-03-27 | — | — | EP | claimed |
| US-4981888-A | Resin compositions | CIBA-GEIGY CORPORATION (US) | 1991-01-01 | — | — | US | claimed |
| EP-0395192-A2 | Process for the preparation of 8-(4-(4-pyrimidin-2-yl-piperazinyl)-butyl)-8-aza-spiro(4.5)decane-7,9-dione (buspiron) | ALKALOIDA VEGYESZETI GYAR (HU) | 1990-10-31 | — | — | EP | claimed |
| US-4411901-A | ANTIPSYCHOTICS | MEAD JOHNSON & COMPANY (US) | 1983-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310433-A1 | Acrylic Polymer Formulations | ALG1, ASAH2, ALG8 | CRBN 3646/4885KDM4E 2562/4885LMNA 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.